NCAM protein and SARS-COV-2 surface proteins : In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome
Copyright © 2020 Elsevier Ltd. All rights reserved..
This study aimed at identifying human neural proteins that can be attacked by cross-reacting SARS-COV-2 antibodies causing Guillain-Barré syndrome. These markers can be used for the diagnosis of Guillain-Barré syndrome (GBS). To achieve this goal, proteins implicated in the development of GBS were retrieved from literature. These human proteins were compared to SARS-COV-2 surface proteins to identify homologous sequences using Blastp. Then, MHC-I and MHC-II epitopes were determined in the homologous sequences and used for further analysis. Similar human and SARS-COV-2 epitopes were docked to the corresponding MHC molecule to compare the binding pattern of human and SARS-COV-2 proteins to the MHC molecule. Neural cell adhesion molecule is the only neural protein that showed homologous sequence to SARS-COV-2 envelope protein. The homologous sequence was part of HLA-A68 and HLA-DQA/HLA-DQB epitopes had a similar binding pattern to SARS-COV-2 envelope protein. Based on these results, the study suggests that NCAM may play a significant role in the immunopathogenesis of GBS. NCAM antibodies can be used as a marker for Guillain-Barré syndrome. However, more experimental studies are needed to prove these results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:145 |
|---|---|
| Enthalten in: |
Medical hypotheses - 145(2020) vom: 15. Dez., Seite 110342 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morsy, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.01.2021 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mehy.2020.110342 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316385328 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316385328 | ||
| 003 | DE-627 | ||
| 005 | 20231225160952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mehy.2020.110342 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316385328 | ||
| 035 | |a (NLM)33069093 | ||
| 035 | |a (PII)S0306-9877(20)32897-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morsy, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NCAM protein and SARS-COV-2 surface proteins |b In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2021 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a This study aimed at identifying human neural proteins that can be attacked by cross-reacting SARS-COV-2 antibodies causing Guillain-Barré syndrome. These markers can be used for the diagnosis of Guillain-Barré syndrome (GBS). To achieve this goal, proteins implicated in the development of GBS were retrieved from literature. These human proteins were compared to SARS-COV-2 surface proteins to identify homologous sequences using Blastp. Then, MHC-I and MHC-II epitopes were determined in the homologous sequences and used for further analysis. Similar human and SARS-COV-2 epitopes were docked to the corresponding MHC molecule to compare the binding pattern of human and SARS-COV-2 proteins to the MHC molecule. Neural cell adhesion molecule is the only neural protein that showed homologous sequence to SARS-COV-2 envelope protein. The homologous sequence was part of HLA-A68 and HLA-DQA/HLA-DQB epitopes had a similar binding pattern to SARS-COV-2 envelope protein. Based on these results, the study suggests that NCAM may play a significant role in the immunopathogenesis of GBS. NCAM antibodies can be used as a marker for Guillain-Barré syndrome. However, more experimental studies are needed to prove these results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Guillain-Barré syndrome | |
| 650 | 4 | |a Major histocompatibility complex | |
| 650 | 4 | |a NCAM | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 7 | |a CD56 Antigen |2 NLM | |
| 650 | 7 | |a Coronavirus Envelope Proteins |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a HLA-A Antigens |2 NLM | |
| 650 | 7 | |a HLA-A*68 antigen |2 NLM | |
| 650 | 7 | |a HLA-DQ alpha-Chains |2 NLM | |
| 650 | 7 | |a HLA-DQ beta-Chains |2 NLM | |
| 650 | 7 | |a HLA-DQA1 antigen |2 NLM | |
| 650 | 7 | |a HLA-DQbeta antigen |2 NLM | |
| 650 | 7 | |a NCAM1 protein, human |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 650 | 7 | |a envelope protein, SARS-CoV-2 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Medical hypotheses |d 1983 |g 145(2020) vom: 15. Dez., Seite 110342 |w (DE-627)NLM00007487X |x 1532-2777 |7 nnns |
| 773 | 1 | 8 | |g volume:145 |g year:2020 |g day:15 |g month:12 |g pages:110342 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mehy.2020.110342 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 145 |j 2020 |b 15 |c 12 |h 110342 | ||